Bcl-2 inhibitors have demonstrated considerable potential as a therapeutic intervention for malignancies, with favorable outcomes both as monotherapy and in conjunction with other pharmacological agents across a wide range of malignancies [24]. Here, BCL2 is linked to cancer.